Search

Art of Drug Choice Header Bar

Editorial Feature:

The Art of Drug Choice

Wet AMD and the Latest Data

Editorially Independent content supported with advertising by Novartis and Alcon.

Navigating Treatment Burden in Wet AMD

Christina Weng, MD, MBA

Show Description +

Christina Y. Weng, MD, MBA, describes the case of a patient diagnosed with wet AMD who found it difficult to navigate treatment burden. Following three monthly doses of aflibercept (Eylea, Regeneron), the patient underwent therapy with brolucizumab (Beovu, Novartis). Listen to a panel of experts discuss this case on the New Retina Radio miniseries The Art of Drug Choice: Wet AMD and the Latest Data.

Posted: 10/22/2020

Keywords:

Age-Related Macular Degeneration (AMD)

•

Wet AMD

Up Next

Outside-the-Box Therapy for Wet AMD

Outside-the-Box Therapy for Wet AMD

Christopher G. Fuller, MD

The Value of Treatment Options in Wet AMD

The Value of Treatment Options in Wet AMD

Justus G. Garweg, MD

Switching to a New Anti-VEGF Agent Early in the Course of Therapy

Switching to a New Anti-VEGF Agent Early in the Course of Therapy

Seenu M. Hariprasad, MD

Extending Duration in a Patient With Polypoidal Choroidal Vasculopathy

Extending Duration in a Patient With Polypoidal Choroidal Vasculopathy

Peter Kertes, MD, FRCS(C)

Managing a Patient With High Treatment Burden and a History of Intraocular Inflammation

Managing a Patient With High Treatment Burden and a History of Intraocular Inflammation

Arshad M. Khanani, MD, MA

Management of IOI After Anti-VEGF Therapy in a 12-year Wet AMD Patient

Management of IOI After Anti-VEGF Therapy in a 12-year Wet AMD Patient

Arshad M. Khanani, MD, MA

Switching Agents Multiple Times in a Long-term Wet AMD Patient

Switching Agents Multiple Times in a Long-term Wet AMD Patient

Lejla Vajzovic, MD

Extending Treatment Intervals in a 90-Year-Old Wet AMD Patient

Extending Treatment Intervals in a 90-Year-Old Wet AMD Patient

Joseph M. Coney, MD

Increasing Treatment Intervals in Wet AMD

Increasing Treatment Intervals in Wet AMD

Arshad M. Khanani, MD

A Breakthrough After Monthly Wet AMD Therapy

A Breakthrough After Monthly Wet AMD Therapy

Nikolas J.S. London, MD

Back to All Videos

Navigating Treatment Burden in Wet AMD

Christina Weng, MD, MBA

Christina Y. Weng, MD, MBA, describes the case of a patient diagnosed with wet AMD who found it difficult to navigate treatment burden. Following three monthly doses of aflibercept (Eylea, Regeneron), the patient underwent therapy with brolucizumab (Beovu, Novartis). Listen to a panel of experts discuss this case on the New Retina Radio miniseries The Art of Drug Choice: Wet AMD and the Latest Data.

Posted: 10/22/2020

Keywords:

Age-Related Macular Degeneration (AMD)

•

Wet AMD

Please log in to leave a comment.

Listen as a Podcast

New Retina Radio

All video episodes of this series are also available as podcast episodes on New Retina Radio.